Letter to the Editor
Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?
¿Debería ser el tocilizumab el tratamiento de primera línea para la neuromielitis óptica junto con el rituximab?
R. Sawaya
, G. Saab, H. Moussa
Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon
Read
1790
Timeswas read the article
314
Total PDF
1476
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 7 | 44 | 7 | 51 |
| 2025 6 | 62 | 7 | 69 |
| 2025 5 | 69 | 3 | 72 |
| 2025 4 | 77 | 6 | 83 |
| 2025 3 | 93 | 4 | 97 |
| 2025 2 | 58 | 5 | 63 |
| 2025 1 | 65 | 6 | 71 |
| 2024 12 | 44 | 2 | 46 |
| 2024 11 | 38 | 2 | 40 |
| 2024 10 | 20 | 0 | 20 |
| 2024 9 | 35 | 4 | 39 |
| 2024 8 | 31 | 7 | 38 |
| 2024 7 | 23 | 2 | 25 |
| 2024 6 | 28 | 6 | 34 |
| 2024 5 | 24 | 4 | 28 |
| 2024 4 | 17 | 3 | 20 |
| 2024 3 | 32 | 0 | 32 |
| 2024 2 | 17 | 3 | 20 |
| 2024 1 | 7 | 3 | 10 |
| 2023 12 | 33 | 14 | 47 |
| 2023 11 | 37 | 10 | 47 |
| 2023 10 | 29 | 11 | 40 |
| 2023 9 | 30 | 1 | 31 |
| 2023 8 | 24 | 5 | 29 |
| 2023 7 | 30 | 3 | 33 |
| 2023 6 | 45 | 2 | 47 |
| 2023 5 | 55 | 11 | 66 |
| 2023 4 | 27 | 7 | 34 |
| 2023 3 | 27 | 4 | 31 |
| 2023 2 | 14 | 10 | 24 |
| 2023 1 | 16 | 16 | 32 |
| 2022 12 | 20 | 14 | 34 |
| 2022 11 | 38 | 13 | 51 |
| 2022 10 | 20 | 5 | 25 |
| 2022 9 | 12 | 6 | 18 |
| 2022 8 | 22 | 6 | 28 |
| 2022 7 | 12 | 12 | 24 |
| 2022 6 | 26 | 4 | 30 |
| 2022 5 | 21 | 5 | 26 |
| 2022 4 | 11 | 5 | 16 |
| 2022 3 | 20 | 10 | 30 |
| 2022 2 | 23 | 8 | 31 |
| 2022 1 | 31 | 9 | 40 |
| 2021 12 | 40 | 14 | 54 |
| 2021 11 | 13 | 24 | 37 |
| 2021 10 | 16 | 11 | 27 |
Show all
